Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 1,694 trials

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Hematological Cancers in Children: New Drug Combination Study

We are testing a combination of Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for children with relapsed or refractory hematological malignancies. The goal is to assess safety and see if it works for patients with specific genetic changes.

Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Takotsubo Syndrome: New Treatment Approaches

We are studying whether a combination of adenosine and dipyridamole improves outcomes for patients with Takotsubo Syndrome. Additionally, we’re testing if apixaban can lower the risk of blood clots in these patients.

Takotsubo Syndrome>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Radiation Therapy

We are studying whether adding stereotactic body radiation therapy to Apalutamide improves treatment outcomes for men with low burden metastatic hormone-sensitive prostate cancer. This trial compares standard treatment alone to the combination therapy.

Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Gastrectomy: Pancreatic Enzyme Supplementation

We are investigating if taking pancreatic enzymes with meals improves quality of life for patients after gastrectomy. This study aims to see how these enzymes may help in recovery.

Patients after Gastrectomy>2 yearsConfirmation phase (III)Investigational MedicinesGastroenterologyInternal Medicine

Generalized Periodontitis: Valaciclovir Treatment Study

We are investigating whether the antiviral drug Valaciclovir can improve treatment outcomes for people with advanced generalized periodontitis. This study compares its effects to standard treatments and a placebo.

Generalized Periodontitis≤3 monthsConfirmation phase (III)Investigational MedicinesInfectious DiseasesOtolaryngology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyNephrology

Acute Myeloid Leukemia: Hydroxyurea and Valproic Acid Study

We are investigating a new treatment combination for patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who cannot receive standard chemotherapy. The study will assess safety, effectiveness, and quality of life.

Acute Myeloid Leukemia6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced Dedifferentiated Liposarcoma: Pemigatinib and Retifanlimab Study

We are studying the effects of two medications on patients with advanced dedifferentiated liposarcoma. The goal is to see if they improve treatment outcomes and quality of life.

Dedifferentiated Liposarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Isolated MMA: Long-Term Study of mRNA-3705

We are evaluating the long-term safety and effects of mRNA-3705 in individuals with Isolated MMA who have participated in earlier studies. This research aims to understand how the treatment impacts health and daily activities over time.

Methylmalonic AciduriaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal Medicine

Oxygen Therapy for AECOPD: Standard vs Targeted Approach

We are investigating whether a targeted oxygen therapy can reduce mortality and improve breathing in patients with acute exacerbations of chronic obstructive pulmonary disease. This study compares it to standard oxygen treatment to see which is more effective.

COPD Exacerbation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Osteoarthritis: Walking Rehabilitation with Anti-Inflammatory Treatment

We are exploring how a specific anti-inflammatory medication can support a walking rehabilitation program for people with hip or knee osteoarthritis. The goal is to see if this combination improves walking ability and overall comfort.

Osteoarthritis of the Hip or Knee≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Acute Myeloid Leukemia: Comparing Treatment Regimens

We are studying two different conditioning regimens for adults with acute myeloid leukemia before stem cell transplantation. The goal is to see which regimen may improve survival and recovery outcomes.

Acute Myeloid Leukemia in Remission>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

H3 K27M-Mutant Diffuse Glioma: ONC201 Treatment Study

We are studying the effects of ONC201 in patients with H3 K27M-mutant diffuse glioma after radiotherapy. The goal is to see if it improves outcomes compared to a placebo.

H3 K27M-Mutant Diffuse GliomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Small Cell Lung Cancer: Niraparib with Immunotherapy

We are studying the effects of adding niraparib to immunotherapy for patients with SLFN11-positive small cell lung cancer. This research aims to see if it improves treatment after initial therapy.

Extensive Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Systemic Lupus Erythematosus: ESK-001 Treatment Study

We are investigating a new medication, ESK-001, for adults with systemic lupus erythematosus to see if it helps improve disease activity and is safe to use. Participants will receive either ESK-001 or a placebo in this study.

Systemic Lupus Erythematosus1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Atrial Fibrillation: WOEST-3 Study

We are exploring a new antithrombotic strategy for patients with atrial fibrillation undergoing heart procedures. The goal is to see if this approach reduces bleeding and heart-related risks compared to standard treatment.

Atrial FibrillationAcute Coronary SyndromeChronic Coronary Syndrome1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine